– USA, CA – Avid Bioservices, Inc. (NASDAQ: CDMO | NASDAQ: CDMOP), a dedicated biologics contract development and manufacturing organization working to improve patient lives by providing high-quality development and manufacturing services to biotechnology and pharmaceutical companies, today announced the appointment of Jeanne Thoma to its Board as an Independent Director.
Ms. Thoma is a seasoned pharmaceutical industry executive with more than 30 years of experience spanning product development and commercialization, as well as operations and supply chain management.
“On behalf of the entire board, I am delighted to welcome Ms. Thoma with her extensive pharmaceutical industry expertise to the Avid board of directors,” said Board chairman, Dr. Joseph Carleone.
“Throughout her 30-year career, which spans tenures with several global leaders in the pharmaceutical and contract manufacturing space, Ms. Thoma has achieved consistent and impressive success in establishing and growing innovative businesses. Her expertise, including her most recent role as president and CEO of a leading pharmaceuticals ingredients company, is particularly relevant to Avid’s CDMO business, offering critical value as we work diligently to continue to grow our client base and revenue,” said CEO, Nicholas Green. “I join our board in welcoming Ms. Thoma, as we all look forward to tapping into her broad skill set and experience to continue to strengthen Avid’s business.”
About Jeanne Thoma
During her 30-year career, Ms. Thoma has successfully built innovative, high-performing businesses that consistently deliver results. She most recently served as president and chief executive officer of SPI Pharma Inc., a global pharmaceuticals ingredients company and an innovative solutions provider of ingredients and drug delivery systems. Before SPI, Ms. Thoma held positions of increasing responsibility at Lonza AG, a Switzerland-based biotech company, most recently as president and chief operating officer of the microbial control business sector. Before joining Lonza, she spent 14 years within the pharma solutions business at BASF Corporation, during which time she held various leadership positions in the areas of sales, marketing, and operations. Ms. Thoma is a member of the board of advisors for the Drug Chemical and Associated Technologies Association and currently sits on the board of directors of ANI Pharmaceuticals.
Ms. Thoma said, “It is an honor to be joining the accomplished group of professionals on the Avid Board, and the dynamic executives leading the company. It is an exciting time for Avid and I am looking forward to supporting their strategic objectives.”
About Avid Bioservices, Inc.
Avid Bioservices is a dedicated contract development and manufacturing organization focused on the development and CGMP manufacturing of biopharmaceutical drug substances derived from mammalian cell culture. The company provides a comprehensive range of process development, CGMP clinical and commercial manufacturing services for the biotechnology and biopharmaceutical industries. With 27 years of experience producing monoclonal antibodies and recombinant proteins, Avid’s services include CGMP clinical and commercial drug substance manufacturing, bulk packaging, release, and stability testing, and regulatory submissions support. For early-stage programs, the company provides a variety of process development activities, including upstream and downstream development and optimization, analytical methods development, testing, and characterization. The scope of our services ranges from standalone process development projects to full development and manufacturing programs through commercialization.
For more information: https://avidbio.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.